Regulation of KRAS Trafficking and Signaling by GPR31

GPR31 对 KRAS 贩运和信号传输的监管

基本信息

项目摘要

PROJECT SUMMARY KRAS is the oncogene most frequently mutated in human cancer. KRAS functions as a molecular switch that regulates signaling pathways only when associated with cellular membranes. KRAS associates with membranes as a consequence of farnesylation that operates in conjunction with a polybasic C-terminus. Efforts to defeat KRAS by blocking farnesylation failed because of alternative enzymes capable of prenylating KRAS. We therefore took an unbiased approach to identify previously unrecognized genes that participate in the membrane association of KRAS. We devised a dual luciferase assay that reports loss of KRAS affinity for membranes and used this assay in a genome-wide siRNA screen. Among the 13 genes identified we were surprised to find a G protein coupled receptor (GPCR) designated GPR31, which is a high affinity receptor for 12-(S)- HETE and has been shown to stimulate MAPK signaling. GPR31 is an understudied GPCR that is included in the Illuminating the Druggable Genome project. We were also surprised to find by co-immunoprecipitation a physical interaction between GPR31 and KRAS, suggesting that GPR31 might act as a secretory pathway chaperone for KRAS as it traffics from endomembrane to the plasma membrane (PM). In preliminary studies we have found that GRP31 and KRAS colocalized on endomembrane and PM and that silencing of GPR31 with siRNA inhibits KRAS dependent cell proliferation and macropinocytosis. We now propose to determine if 12-(S)-HETE signaling through GPR31 regulates KRAS trafficking and signaling with three Specific Aims. Aim 1. Ligation of GPR31 with 12-(S)-HETE and Interaction of GPR31 with KRAS. We will measure the interaction between GPR31 and KRAS by co-immunoprecipitation and FRET ± 12-(S)-HETE or control eicosinoids. Aim 2. Ligation of GPR31 with 12-(S)-HETE and Trafficking of KRAS. We will study KRAS trafficking from endomembrane to PM using live cell imaging ± 12-(S)-HETE. Aim 3. Ligation of GPR31 with 12-(S)-HETE and KRAS activation. We will study KRAS signaling ± 12-(S)-HETE. The prosecution of these aims will determine if GPR31 signaling regulates KRAS and thereby prioritize GPR31 for anti- cancer drug discovery. !
项目总结 KRAS是人类癌症中突变最频繁的癌基因。KRAS的职能是 仅当与细胞相关时才调节信号通路的分子开关 膜。KRAS作为法尼化的结果与膜结合 与多碱的C-末端一起工作。通过屏蔽击败KRAS的努力 法尼化失败是因为替代的酶能够使KRAS提前甲基化。我们 因此采取了一种不偏不倚的方法来识别以前未被识别的基因 参加KRAS膜协会。我们设计了一种双荧光素酶测定法 报告了KRAS膜亲和力的丧失,并在全基因组范围内使用了这一分析方法 SiRNA筛选。在确认的13个基因中,我们惊讶地发现了一种G蛋白 偶联受体命名为GPR31,是12-(S)-的高亲和力受体。 HETE和已被证明刺激MAPK信号转导。GPR31是一个未被研究的 这是包括在照亮可药物基因组项目中的GPCR。我们是在 我还惊讶地发现,通过免疫共沉淀,GPR31之间存在物理相互作用 和KRAS,提示GPR31可能作为KRAS的分泌途径伴侣 因为它从内膜运输到质膜(PM)。在初步研究中 我们发现GRP31和KRAS共定位于内膜和PM上,并且 SiRNA沉默GPR31抑制KRAS依赖的细胞增殖和 巨噬细胞增多症。我们现在建议确定12-(S)-HETE信号是否通过 GPR31管理KRAS贩运和信号,有三个具体目标。目标1。 GPR31与12-(S)-HETE的连接及与KRAS的相互作用。我们会 免疫共沉淀和FRET检测GPR31与KRAS的相互作用 ±12-(S)-HETE或对照二十烷基类化合物。目的2.用12-(S)-HETE连接GPR31和 贩卖KRAS。我们将研究KRAS从子宫内膜到PM的运输 活细胞成像±12-(S)-HETE。目的3.GPR31与12-(S)-HETE和KRAS的连接 激活。我们将研究KRAS信号转导±12-(S)-HETE。对这些目标的起诉 将确定GPR31信号是否调节KRAS,从而确定GPR31对抗 抗癌药物的发现。 好了!

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK Reid PHILIPS其他文献

MARK Reid PHILIPS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK Reid PHILIPS', 18)}}的其他基金

FASEB SRC: Structure and Function of Small GTPases
FASEB SRC:小 GTP 酶的结构和功能
  • 批准号:
    10463260
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Differential function and tumor vulnerabilities revealed by RAS membrane trafficking
RAS 膜运输揭示的差异功能和肿瘤脆弱性
  • 批准号:
    10468873
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Differential function and tumor vulnerabilities revealed by RAS membrane trafficking
RAS 膜运输揭示的差异功能和肿瘤脆弱性
  • 批准号:
    10688011
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Medical Scientist Research Service Award
医学科学家研究服务奖
  • 批准号:
    10198956
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Medical Scientist Research Service Award
医学科学家研究服务奖
  • 批准号:
    10417095
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Differential function and tumor vulnerabilities revealed by RAS membrane trafficking
RAS 膜运输揭示的差异功能和肿瘤脆弱性
  • 批准号:
    10237382
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Differential function and tumor vulnerabilities revealed by RAS membrane trafficking
RAS 膜运输揭示的差异功能和肿瘤脆弱性
  • 批准号:
    10053541
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Role of nonsense mediated RNA decay in pancreatic cancer
无义介导的RNA衰变在胰腺癌中的作用
  • 批准号:
    10229380
  • 财政年份:
    2018
  • 资助金额:
    $ 16.95万
  • 项目类别:
Role of nonsense mediated RNA decay in pancreatic cancer
无义介导的RNA衰变在胰腺癌中的作用
  • 批准号:
    9447641
  • 财政年份:
    2018
  • 资助金额:
    $ 16.95万
  • 项目类别:
Role of nonsense mediated RNA decay in pancreatic cancer
无义介导的RNA衰变在胰腺癌中的作用
  • 批准号:
    10410447
  • 财政年份:
    2018
  • 资助金额:
    $ 16.95万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 16.95万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 16.95万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 16.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了